In vitro activity of delafloxacin and microbiological response against fluoroquinolone susceptible and non-susceptible S. aureus isolates from two Phase 3 Studies of acute bacterial skin and skin structure infections (ABSSSI).
In vitro activity of delafloxacin and microbiological response against fluoroquinolone susceptible and non-susceptible S. aureus isolates from two Phase 3 Studies of acute bacterial skin and skin structure infections (ABSSSI). by McCurdy S, Lawrence L, Quintas M, Woosley L, Flamm R, Tseng C and Cammarata S published in Antimicrob. Agents Chemother. 2017; 61 (9): e007722017
Gepotidacin (GSK2140944) in vitro activity against Gram-positive and Gram-negative bacteria.
Gepotidacin (GSK2140944) in vitro activity against Gram-positive and Gram-negative bacteria. by Flamm RK, Farrell DJ, Rhomberg PR, Scangarella-Oman NE and Sader HS published in Antimicrob. Agents Chemother. 2017; 61 (7): e00468-17
Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae.
Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. by Castanheira M, Huband MD, Mendes RE and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (9): e00567
In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary ABSSSI Isolates from the United States (2014-2016): Results from the SENTRY Antimicrobial Surveillance Program
In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary ABSSSI Isolates from the United States (2014-2016): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-4
In Vitro Activity of Telavancin against Staphylococcus aureus Causing Pneumonia or Skin and Skin Structure Infections with Concomitant Bloodstream Infections in United States Hospitals (2012-2016)
In Vitro Activity of Telavancin against Staphylococcus aureus Causing Pneumonia or Skin and Skin Structure Infections with Concomitant Bloodstream Infections in United States Hospitals (2012-2016). Lead author: L Duncan, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-141
Antimicrobial Synergistic Effect of a New Anti-Gram-Positive Agent Tested in Combination with a Polymyxin Derivative against Gram-Negative Pathogens, Including ESKAPE Group Organisms
Antimicrobial Synergistic Effect of a New Anti-Gram-Positive Agent Tested in Combination with a Polymyxin Derivative against Gram-Negative Pathogens, Including ESKAPE Group Organisms. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-23
In Vitro Activity of Plazomicin and Comparator Agents against Urinary Tract Infection Isolates from the United States and Europe
In Vitro Activity of Plazomicin and Comparator Agents against Urinary Tract Infection Isolates from the United States and Europe. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-10
Emergence of Proteeae Species Isolates Carrying blaIMP-27-like in United States and Mexico
Emergence of Proteeae Species Isolates Carrying blaIMP-27-like in United States and Mexico. Lead author: L Deshpande, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Sunday-125
Intrinsic Resistance Mechanisms Detected Among Ceftazidime-Avibactam-Susceptible and -Resistant Pseudomonas aeruginosa Isolates Collected from United States Hospitals (2015)
Intrinsic Resistance Mechanisms Detected Among Ceftazidime-Avibactam-Susceptible and -Resistant Pseudomonas aeruginosa Isolates Collected from United States Hospitals (2015). Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA.
#Sunday-166
Antimicrobial Activity of Ceftobiprole When Tested against Isolates from Diabetic Foot Infections (2013-2016)
Antimicrobial Activity of Ceftobiprole When Tested against Isolates from Diabetic Foot Infections (2013-2016). Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-6
Aminoglycoside-Resistance Genes Among 2014-2015 US Carbapenem-Resistant Enterobacteriaceae Isolates and Activity of Plazomicin against Characterized Isolates
Aminoglycoside-Resistance Genes Among 2014-2015 US Carbapenem-Resistant Enterobacteriaceae Isolates and Activity of Plazomicin against Characterized Isolates. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-9
Antimicrobial Susceptibility Trends among Staphylococcus aureus from US Hospitals: Results from 7 years of the Ceftaroline (AWARE) Surveillance Program (2009-2015)
Antimicrobial Susceptibility Trends among Staphylococcus aureus from US Hospitals: Results from 7 years of the Ceftaroline (AWARE) Surveillance Program (2009-2015). Lead author: H Sader presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-142
Activity of Solithromycin and Comparators against Respiratory Tract Pathogens Collected in the 2016 Global SENTRY Surveillance Program
Activity of Solithromycin and Comparators against Respiratory Tract Pathogens Collected in the 2016 Global SENTRY Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-7
Antimicrobial Activity of Ceftobiprole When Tested against Contemporary Isolates from US Medical Centers (2016)
Antimicrobial Activity of Ceftobiprole When Tested against Contemporary Isolates from US Medical Centers (2016). Lead author: R Flamm, presented at ASM Microbe 2017, New Orleans, Louisiana, USA
# Sunday-12
Updated Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bloodstream Infections in United States and European Hospitals (2014-2016)
Updated Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bloodstream Infections in United States and European Hospitals (2014-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-33
Potentiation of Clarithromycin When Combined with a New Cationic Peptide against Gram-negative Clinical Isolates and Molecular Analysis of Macrolide Resistance Mechanisms by Next-Generation Sequencing
Potentiation of Clarithromycin When Combined with a New Cationic Peptide against Gram-negative Clinical Isolates and Molecular Analysis of Macrolide Resistance Mechanisms by Next-Generation Sequencing. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-162
Synergistic Effect of Novel Gyrase Inhibitor Agents (SPR750 and SPR751) in Combination with a Polymyxin Derivative (SPR741) against Recent Acinetobacter baumannii and Enterobacteriaceae
Synergistic Effect of Novel Gyrase Inhibitor Agents (SPR750 and SPR751) in Combination with a Polymyxin Derivative (SPR741) against Recent Acinetobacter baumannii and Enterobacteriaceae. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Sunday-13
In vitro Antibacterial Activity of Omadacycline and Comparators against Key Respiratory, Skin and Skin Structure, and Urinary Tract Pathogens Collected from the United States and Europe during the 2016 SENTRY Antimicrobial Surveillance Program
In vitro Antibacterial Activity of Omadacycline and Comparators against Key Respiratory, Skin and Skin Structure, and Urinary Tract Pathogens Collected from the United States and Europe during the 2016 SENTRY Antimicrobial Surveillance Program. Lead author: M Huband presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-45
Multilaboratory Broth Microdilution MIC Reproducibility Study for GSK3342830, a Novel Catechol-Cephem
Multilaboratory Broth Microdilution MIC Reproducibility Study for GSK3342830, a Novel Catechol-Cephem. Lead author: P Rhomberg, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-287
Global Surveillance: Susceptibility of Ceftolozane-Tazobactam against Pseudomonas aeruginosa, Klebsiella spp., and Escherichia coli Isolates Collected in Asia-Pacific, North and Latin America, and Europe from 2011-2016
Global Surveillance: Susceptibility of Ceftolozane-Tazobactam against Pseudomonas aeruginosa, Klebsiella spp., and Escherichia coli Isolates Collected in Asia-Pacific, North and Latin America, and Europe from 2011-2016. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-29
Antimicrobial Activity of Meropenem-WCK 4234 (WCK 5999) against Clinical Isolates of Acinetobacter spp. Collected Worldwide and Stratified by Infection Type
Antimicrobial Activity of Meropenem-WCK 4234 (WCK 5999) against Clinical Isolates of Acinetobacter spp. Collected Worldwide and Stratified by Infection Type. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Saturday-97
Fosfomycin In Vitro Activity against Bacteria with Various Mechanisms of Resistance to Other Antibacterials from US Hospitals
Fosfomycin In Vitro Activity against Bacteria with Various Mechanisms of Resistance to Other Antibacterials from US Hospitals. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-61
Evaluation of Fosfomycin Activity When Combined with Selected Antimicrobial Agents and Tested against Bacterial Isolates Using Checkerboard Methods
Evaluation of Fosfomycin Activity When Combined with Selected Antimicrobial Agents and Tested against Bacterial Isolates Using Checkerboard Methods. Lead author: P Rhomberg, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-406
Activity of Fusidic Acid against Recent Clinical Isolates of Staphylococci Collected from United States Hospitals in 2016 as Part of the SENTRY Antimicrobial Surveillance Program
Activity of Fusidic Acid against Recent Clinical Isolates of Staphylococci Collected from United States Hospitals in 2016 as Part of the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-56
In Vitro Activity of LYS228 against Enterobacteriaceae, Including Molecularly Characterized Multidrug-Resistant Isolates
In Vitro Activity of LYS228 against Enterobacteriaceae, Including Molecularly Characterized Multidrug-Resistant Isolates. Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-293
Fosfomycin Activity When Tested against Gram-Positive and Gram-Negative US Isolates Collected by the SENTRY Antimicrobial Surveillance Program
Fosfomycin Activity When Tested against Gram-Positive and Gram-Negative US Isolates Collected by the SENTRY Antimicrobial Surveillance Program. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-57
Correlation of Reference Agar Dilution MIC Values and Kirby-Bauer Disk Diffusion Testing for Fosfomycin against Gram-Positive and Gram-Negative Bacteria
Correlation of Reference Agar Dilution MIC Values and Kirby-Bauer Disk Diffusion Testing for Fosfomycin against Gram-Positive and Gram-Negative Bacteria. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Saturday-411
Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents
Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-414
Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates, Including Carbapenem-Resistant and Carbapenemase-Producing Isolates, Collected in United States (US) Hospitals During 2016
Meropenem-Vaborbactam Activity against Enterobacteriaceae Isolates, Including Carbapenem-Resistant and Carbapenemase-Producing Isolates, Collected in United States (US) Hospitals During 2016. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-58
Tedizolid Activity against Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis in United States and European Hospitals (2014-2016)
Tedizolid Activity against Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis in United States and European Hospitals (2014-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-341
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Pseudomonas aeruginosa Isolates with Various Resistant Phenotypes from US Hospitals
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2014-2016) Pseudomonas aeruginosa Isolates with Various Resistant Phenotypes from US Hospitals. Lead author: D Shortridge, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-50
Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2015)
Serotype Distributions and Analysis of Susceptibility Profiles of Streptococcus pneumoniae Causing Infections in Adult Patients in the United States (2009-2015). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-129
Meropenem-Vaborbactam (CarbavanceTM) MIC and Zone Diameter Quality Control Ranges Using a CLSI M23-A4 Multi-Laboratory Study Design
Meropenem-Vaborbactam (CarbavanceTM) MIC and Zone Diameter Quality Control Ranges Using a CLSI M23-A4 Multi-Laboratory Study Design. Lead author: M Huband, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-417
Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) When Tested against Bacterial Isolates from Patients Hospitalized with Pneumonia
Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) When Tested against Bacterial Isolates from Patients Hospitalized with Pneumonia. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-52
Susceptibility of Ceftolozane-Tazobactam against Isolates Collected from Intensive Care Unit Patients in US Hospitals from 2014-2016
Susceptibility of Ceftolozane-Tazobactam against Isolates Collected from Intensive Care Unit Patients in US Hospitals from 2014-2016. Lead author: M Pfaller, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-76
Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents
Time Kill Analyses of Concerning Gram-Negative Bacteria with Fosfomycin Alone and in Combination with Select Antimicrobial Agents. Lead author: R Flamm, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-414
Impact of Changes in Growth Medium, Inoculum Density, and Incubation Conditions on the In Vitro Antimicrobial Activity of Plazomicin
Impact of Changes in Growth Medium, Inoculum Density, and Incubation Conditions on the In Vitro Antimicrobial Activity of Plazomicin. Lead author: L Duncan presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-410
In Vitro Activity and Potency of the Novel Oxazolidinone MRX-I Tested against Contemporary Clinical Isolates of Gram-Positive Bacteria
In Vitro Activity and Potency of the Novel Oxazolidinone MRX-I Tested against Contemporary Clinical Isolates of Gram-Positive Bacteria. Lead author: H Sader, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
#Friday-343
Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Isolates Harboring β-Lactamase Genes Detected Using Whole Genome Sequencing Analysis
Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Isolates Harboring β-Lactamase Genes Detected Using Whole Genome Sequencing Analysis. Lead author: M Castanheira, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-57
Oritavancin In Vitro Activity Against a Collection of Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis, in United States and European Hospitals (2012-2016)
Oritavancin In Vitro Activity Against a Collection of Gram-Positive Clinical Isolates Causing Bone and Joint Infections, Including Osteomyelitis, in United States and European Hospitals (2012-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-342
Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Infections in United States Hospitals (2014-2016)
Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Infections in United States Hospitals (2014-2016). Lead author: R Mendes, presented at ASM Microbe 2017, June 1-5, New Orleans, Louisiana, USA
# Friday-340
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against gram-negative organisms producing clinically relevant beta-lactamases.
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against gram-negative organisms producing clinically relevant beta-lactamases. by Sader HS, Rhomberg PR, Flamm RK, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2017; 72 (6): 1696-1703
Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012-2015) of the International Network for Optimal Resistance Monitoring program in the United States.
Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012-2015) of the International Network for Optimal Resistance Monitoring program in the United States. by Sader HS, Huband MD, Castanheira M and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (3): e02252
Antimicrobial activity of high-proportion cefepime-tazobactam (WCK 4282) against a large number of gram-negative isolates collected worldwide in (2014).
Antimicrobial activity of high-proportion cefepime-tazobactam (WCK 4282) against a large number of gram-negative isolates collected worldwide in (2014). by Sader HS, Castanheira M, Mendes RE, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2017; 61 (4): e02409
Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).
Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). by Sader HS, Castanheira M, Jones RN and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2017; 87 (3): 261-265
WCK 5222 (cefepime-zidebactam) antimicrobial activity tested against clinical isolates of gram-negative bacteria collected worldwide (2015).
WCK 5222 (cefepime-zidebactam) antimicrobial activity tested against clinical isolates of gram-negative bacteria collected worldwide (2015). by Sader HS, Castanheira M, Huband M, Jones RN and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (5): 00072
Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2011-2015).
Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2011-2015). by Sader HS, Castanheira M and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (4): e02083
Activities of omadacycline and comparator agents when tested against Staphylococcus aureus from a surveillance program conducted in North America and Europe.
Activities of omadacycline and comparator agents when tested against Staphylococcus aureus from a surveillance program conducted in North America and Europe. by Pfaller MA, Rhomberg PR, Huband MD and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (3): e02411
Activity of a long-acting Echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY (2014) Antifungal Surveillance Program.
Activity of a long-acting Echinocandin (CD101) and seven comparator antifungal agents tested against a global collection of contemporary invasive fungal isolates in the SENTRY (2014) Antifungal Surveillance Program. by Pfaller MA, Messer SA, Rhomberg PR and Castanheira M published in Antimicrob. Agents Chemother. 2017; 61 (3): e02045
Ceftaroline activity against multidrug-resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and molecular characterization of a single ceftaroline nonsusceptible isolate.
Ceftaroline activity against multidrug-resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and molecular characterization of a single ceftaroline nonsusceptible isolate. by Pfaller MA, Mendes RE, Flamm RK, Jones RN and Sader HS published in Microb. Drug Resist. 2017; 23 (5): 571-579
